Get the latest news, insights, and market updates on DVAX (Dynavax Technologies Corporation). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Sanofi Buyout Ends Dynavax Listing And Shifts Vaccine Upside To Group
Sanofi has completed its acquisition of Dynavax Technologies Corporation (NasdaqGS:DVAX), closing the transaction and changing the company’s ownership structure. Following the deal, Dynavax has been delisted from Nasdaq and removed from major stock indices, ending its status as a publicly traded company. The acquisition triggered broad changes to Dynavax’s board and executive leadership team, reshaping corporate governance. Dynavax, known for its work in vaccines and immunology, now sits... Feb 11, 2026 - $DVAX
Is It Time To Reassess Dynavax (DVAX) After The Agreed Sanofi Cash Acquisition Deal
If you are looking at Dynavax Technologies and wondering whether the current share price reflects its true worth, this article will walk you through what the numbers actually say about value. The stock closed at US$15.50 recently, with returns of 0.1% over 7 days, 0.6% over 30 days, 0.8% year to date, 22.0% over 1 year, 36.7% over 3 years and 58.5% over 5 years, which may have some investors reassessing both upside potential and risk. Recent news coverage around Dynavax has focused on its... Feb 10, 2026 - $DVAX
Press Release: Sanofi completes the acquisition of Dynavax
Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition includes Dynavax’s adult hepatitis B vaccine HEPLISAV-B, which is currently marketed in the US and is differentiated by its two-dose regimen over one month. It also includes Dynavax’s shingles vaccine candidate (Z-1018), which is currently in phase 1/2 studies, and additional vaccine pipeline projects. Th Feb 10, 2026 - $DVAX
A Look At Dynavax Technologies (DVAX) Valuation As Pipeline Prospects Meet Conflicting Fair Value Estimates
Dynavax Technologies stock overview Dynavax Technologies (DVAX) has been drawing attention from investors primarily for its role as a commercial stage vaccine producer, with products and candidates spanning hepatitis B, plague and shingles, as well as multiple public sector collaborations. See our latest analysis for Dynavax Technologies. At a share price of $15.50, Dynavax Technologies has mostly moved sideways in the very short term. However, a 90 day share price return of 37.66% and 1 year... Feb 10, 2026 - $DVAX
High Growth Tech Stocks To Watch In The US January 2026
As of January 2026, the U.S. stock market has experienced a notable rebound, with major indices such as the Nasdaq, Dow Jones Industrial Average, and S&P 500 each rising about 1.2% following geopolitical developments that eased investor concerns. In this dynamic environment, high-growth tech stocks in the United States continue to capture attention due to their potential for innovation and resilience amidst fluctuating market conditions; identifying promising stocks often involves assessing... Jan 22, 2026 - $DVAX
Jim Cramer Highlights Sanofi’s Bid for Dynavax
Dynavax Technologies Corporation (NASDAQ:DVAX) is one of the stocks Jim Cramer recently looked at. When a caller noted that they bought the stock three years ago for around $12, Cramer remarked: “Congratulations. You know that one’s done. They got that nice bid from Sanofi. I’m going to actually go out there and talk to them […] Jan 14, 2026 - $DVAX
Is It Time To Reassess Dynavax Technologies (DVAX) After Its Recent Share Price Surge
If you are asking whether Dynavax Technologies is reasonably priced at its current level, this article will walk through what the numbers are saying about the stock’s value. Dynavax shares recently closed at US$15.41, with returns of 0.2% over the last 7 days, 41.4% over 30 days, 0.2% year to date, 22.0% over 1 year, 35.8% over 3 years, and 200.4% over 5 years, which may catch the eye of investors weighing upside against risk. Recent attention on Dynavax has been shaped by ongoing interest... Jan 11, 2026 - $DVAX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple